Stock Track | Halozyme Therapeutics Soars 5.24% After-Hours on Q2 Earnings Beat and Raised 2026 Guidance

Stock Track08-07

Halozyme Therapeutics (HALO) stock surged 5.24% in after-hours trading following the release of its second-quarter financial results, which significantly exceeded Wall Street expectations.

The company reported adjusted earnings per share of $2.28, far surpassing the consensus estimate of $1.84, while revenue climbed 48% year-over-year to $481 million, beating the forecast of $407.5 million. The strong performance was driven by a 50% jump in royalty revenue from partner products such as VYVGART Hytrulo and DARZALEX SC, along with higher product sales and five new collaboration agreements signed year-to-date.

Halozyme also raised its full-year 2026 outlook, now projecting total revenue between $1.835 billion and $1.910 billion and non-GAAP diluted EPS in the range of $8.65 to $9.00, up from its prior guidance. Additionally, the company repurchased $332.8 million worth of shares during the quarter, further signaling confidence in its growth trajectory.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1128326085?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-07 04:32","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1128326085","market":"sg","top_or_hot":-1,"title":"Stock Track | Halozyme Therapeutics Soars 5.24% After-Hours on Q2 Earnings Beat and Raised 2026 Guidance","media":"Stock Track","content":"<p>Halozyme Therapeutics (HALO) stock surged 5.24% in after-hours trading following the release of its second-quarter financial results, which significantly exceeded Wall Street expectations.</p>\n<p>The company reported adjusted earnings per share of $2.28, far surpassing the consensus estimate of $1.84, while revenue climbed 48% year-over-year to $481 million, beating the forecast of $407.5 million. The strong performance was driven by a 50% jump in royalty revenue from partner products such as VYVGART Hytrulo and DARZALEX SC, along with higher product sales and five new collaboration agreements signed year-to-date.</p>\n<p>Halozyme also raised its full-year 2026 outlook, now projecting total revenue between $1.835 billion and $1.910 billion and non-GAAP diluted EPS in the range of $8.65 to $9.00, up from its prior guidance. Additionally, the company repurchased $332.8 million worth of shares during the quarter, further signaling confidence in its growth trajectory.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Halozyme Therapeutics Soars 5.24% After-Hours on Q2 Earnings Beat and Raised 2026 Guidance</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Halozyme Therapeutics Soars 5.24% After-Hours on Q2 Earnings Beat and Raised 2026 Guidance\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-08-07 04:32</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Halozyme Therapeutics (HALO) stock surged 5.24% in after-hours trading following the release of its second-quarter financial results, which significantly exceeded Wall Street expectations.</p>\n<p>The company reported adjusted earnings per share of $2.28, far surpassing the consensus estimate of $1.84, while revenue climbed 48% year-over-year to $481 million, beating the forecast of $407.5 million. The strong performance was driven by a 50% jump in royalty revenue from partner products such as VYVGART Hytrulo and DARZALEX SC, along with higher product sales and five new collaboration agreements signed year-to-date.</p>\n<p>Halozyme also raised its full-year 2026 outlook, now projecting total revenue between $1.835 billion and $1.910 billion and non-GAAP diluted EPS in the range of $8.65 to $9.00, up from its prior guidance. Additionally, the company repurchased $332.8 million worth of shares during the quarter, further signaling confidence in its growth trajectory.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"HALO","symbol_name":"奥洛兹美医疗","start_time":0,"source_url":"","article_id":"1128326085","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1128326085","pubTimestamp":1786048363,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Halozyme Therapeutics (HALO) stock surged 5.24% in after-hours trading following the release of its second-quarter financial results, which significantly exceeded Wall Street expectations. The...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"HALO":"奥洛兹美医疗"},"translate_title":"股票跟踪 | Halozyme Therapeutics 第二季度盈利超出预期，盘后股价飙升 5.24%，并上调 2026 年指引","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"HALO":1},"content_text":"Halozyme Therapeutics (HALO) stock surged 5.24% in after-hours trading following the release of its second-quarter financial results, which significantly exceeded Wall Street expectations.\nThe company reported adjusted earnings per share of $2.28, far surpassing the consensus estimate of $1.84, while revenue climbed 48% year-over-year to $481 million, beating the forecast of $407.5 million. The strong performance was driven by a 50% jump in royalty revenue from partner products such as VYVGART Hytrulo and DARZALEX SC, along with higher product sales and five new collaboration agreements signed year-to-date.\nHalozyme also raised its full-year 2026 outlook, now projecting total revenue between $1.835 billion and $1.910 billion and non-GAAP diluted EPS in the range of $8.65 to $9.00, up from its prior guidance. Additionally, the company repurchased $332.8 million worth of shares during the quarter, further signaling confidence in its growth trajectory.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1128326085","isCrawlerRequest":true}